---
document_datetime: 2026-01-06 11:03:26
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/obodence-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: obodence-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 16.1253625
conversion_datetime: 2026-01-10 10:56:29.005591
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Obodence

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                     |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 05/01/2026                          |                                             | SmPC                             | To update Section 4.4 of the SmPC regarding |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000319278                     | Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a (Type IB) - To update Section 4.4 of the SmPC regarding treatment discontinuation following assessment of the same change for the reference product Prolia. Additionally, the MAH takes the opportunity to align the PI with the QRD template, and to update the PI in DA, DE, ET, FI, IS, and RO to correct typographic errors.   |            | treatment discontinuation following assessment of the same change for the reference product Prolia.                                                                                                                                                                                                                                                           |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000312464 | B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.d Change in storage conditions of the finished product or the diluted/reconstituted product - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                     | 26/11/2025 | SmPC and PL                                                                                                                                                                                                                                                                                                                                                   |
| Variation type IB / EMA/VR/0000291542 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be                                                                                                                                                                                                                                                                                                                                  | 05/09/2025 | SmPC To update sections 5.1, of the SmPC to include the wording regarding study results of glucocorticoid- induced osteoporosis paediatric patients following assessment of the same change for the reference product. Additionally, the MAH takes the opportunity to align the PI with the QRD template, to make minor editorial changes in section 4.2, 4.8 |

<div style=\"page-break-after: always\"></div>

|                                       | submitted by the MAH - Accepted To update sections 5.1, of the SmPC to include the wording regarding study results of glucocorticoid-induced osteoporosis paediatric patients following assessment of the same change for the reference product. Additionally, the MAH takes the opportunity to align the PI with the QRD template, to make minor editorial changes in section 4.2, 4.8 and 5.2 of the SmPC and to update the PI in DE, FR, and HU to correct typographic errors.   |            |     | and 5.2 of the SmPC and to update the PI in DE, FR, and HU to correct typographic errors.   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000278398 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.k New storage site of Master Cell Bank and/or Working Cell Banks - Accepted                                                         | 20/06/2025 | N/A |                                                                                             |
| Variation type IA / EMA/VR/0000276241 | B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.e Change to an approved stability protocol - Accepted                                                                                                                                                                                                                                                                                                                                    | 05/06/2025 | N/A |                                                                                             |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000263754   | 06/05/2025   | SmPC, Labelling and PL   | To update sections 4.2, 4.4, 4.6, 4.8, 5.1, 6.4, 6.5, and 10 of the SmPC, section 9 of the Labelling, and sections 2, 4, and 5 of the PL to update safety information including a warning regarding hypocalcaemia, reports of life-threatening events and fatal cases occurred in the post marketing setting, a post-marketing observational study (20090522) results, and the information regarding osteonecrosis of the jaw accordingly following assessment of the same change for the reference product Prolia via procedures EMEA/H/C/001120/II/0099 and EMEA/H/C/001120/II/0100.   |
|-----------------------------------------|--------------|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>